propafenone has been researched along with Tachycardia in 95 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the efficacy of propafenone in preventing atrial tachyarrhythmias after cardiac surgery, and the possible relationships between CYP2D6 polymorphism and the efficacy, pharmacokinetics, and tolerability of propafenone." | 9.13 | Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial. ( Bail, D; Böhm, JO; Delabar, U; Drescher, S; Eichelbaum, M; Engel, C; Fux, R; Gleiter, CH; Hellberg, KD; Hofmann, U; Igel, S; Jägle, C; Kivistö, KT; Marx, C; Meisner, C; Mörike, K; Rein, JG; Schaeffeler, E; Schwab, M; Wagner, F; Ziemer, G, 2008) |
| "The combination of propafenone and mexiletine is effective in suppressing the induction of ventricular tachycardia in some patients refractory to procainamide and propafenone alone." | 9.07 | Propafenone-mexiletine combination for the treatment of sustained ventricular tachycardia. ( Boone, J; Kerr, CR; Murdock, CJ; Yeung-Lai-Wah, JA, 1992) |
| "The efficacy of propafenone in preventing induction of ventricular tachycardia was evaluated in 25 consecutive patients (mean age 62 +/- 8 years) with remote myocardial infarction who underwent programmed electrical stimulation for ventricular arrhythmia using up to three extra-stimuli after basic drive at the right ventricular apex." | 9.06 | Efficacy of propafenone in preventing ventricular tachycardia: inverse correlation with rate-related prolongation of conduction time. ( Dubuc, M; Kus, T; Lambert, C; Shenasa, M, 1990) |
| " Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained." | 9.06 | Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. ( Campa, MA; Dubuc, M; Kus, T; Lambert, C; Rosengarten, M; Shenasa, M, 1989) |
| "Sixteen patients with ventricular tachycardia (VT) or nonfatal cardiac arrest were treated with propafenone (P), 900 mg/day." | 9.05 | Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. ( Connolly, SJ; Echt, DS; Kates, RE; Lebsack, CS; Mason, JW; Winkle, RA, 1983) |
| "The effects of the antiarrhythmic agent propafenone were evaluated in 25 patients with recurrent symptomatic ventricular tachycardia." | 9.05 | Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia. ( Browne, KF; Chilson, DA; Heger, JJ; Prystowsky, EN; Zipes, DP, 1985) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 7.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "We present two cases of proarrhythmia after propafenone treatment." | 7.74 | [Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter]. ( Jastrzebski, M, 2008) |
| "Amiodarone, a class III antiarrhythmic drug, is one of the most effective drugs used in the treatment of ventricular and paroxysmal supraventricular tachyarrhythmia." | 7.74 | Acute pancreatitis and amiodarone: a case report. ( Chen, CY; Chen, YY; Leung, KK, 2007) |
| "The effects of procainamide and propafenone on the composition of the excitable gap (EG) were studied in a canine model of atrial flutter (AFI) around the tricuspid valve." | 7.69 | Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. ( Derakhchan, K; Kus, T; Lambert, C; Pagé, P, 1994) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 7.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "105 sequential patients with ventricular arrhythmias in a basal ECG-H recording, that were evaluated within 1 year with a new recording on amiodarone or propafenone, without major clinical events or therapeutic changes between the two recordings." | 7.68 | [Amiodarone and propafenone: evaluation using serial Holter recordings in patients with ventricular arrhythmia]. ( Adragão, P; Bonhorst, D; Seabra-Gomes, R; Ventosa, A, 1990) |
| "To clarify the risk-benefit ratio involved in association of antiarrhythmic drugs, a combined therapy of amiodarone and propafenone was tested by means of continuous electrocardiographic monitoring, analysis of levels of the drug in the plasma and programmed electrical stimulation in a selected group of 10 patients who had left ventricular dysfunction and spontaneous relapses of sustained ventricular tachycardia despite treatment with amiodarone." | 7.68 | The use of associated propafenone in patients with amiodarone-resistant ventricular tachycardia. ( Camerini, F; Chersevani, D; Dreas, L; Humar, F; Maras, P; Morgera, T, 1991) |
| "To determine the electrophysiological properties of oral propafenone, 50 patients (39 male and 11 female, aged 31 to 80 years) with sustained ventricular tachycardia or ventricular fibrillation underwent serial electrophysiological drug testing, using propafenone (750 to 900 mg daily) as the anti-arrhythmic regimen of first choice." | 7.68 | Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation. ( Frohner, K; Hief, C; Podczeck, A; Steinbach, KK; Stix, G, 1991) |
| "Propafenone was administered to 29 patients who had multiple episodes of recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) despite previous antiarrhythmic therapy." | 7.67 | Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy. ( Heger, JJ; Hubbard, J; Miles, WM; Prystowsky, EN; Zipes, DP, 1984) |
| "0 mg/kg body weight) and oral (300 to 375 mg/d) diprafenone was studied in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia." | 7.67 | Diprafenone for treatment of Wolff-Parkinson-White syndrome. ( Geiger, M; Kuck, KH; Kunze, KP; Schlüter, M, 1989) |
| "Thirty-two men with chronic ventricular arrhythmias responded to propafenone, a new potent antiarrhythmic agent, in short-term trials with 85% or greater reduction of total ventricular premature complexes (VPCs) per hour, 95% or greater reduction of ventricular couplets (VCs) per hour, and 100% abolition of ventricular tachycardia (VT) beats per 24 hours." | 7.67 | Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience. ( Baker, BJ; de Soyza, N; Dinh, H; Murphy, ML, 1988) |
| "The effect of oral propafenone on prevention of pacing-induced ventricular tachycardia (VT) was studied in 11 patients." | 7.67 | [Treatment of recurrent ventricular tachycardias using oral propafenone]. ( Cointe, R; Gérard, R; Labrunie, P; Lévy, S; Metge, M; Valeix, B; Vrancea, F, 1985) |
| "The purpose of our study was to assess the efficacy of Propafenon in comparison with Disopyramide in the long-term treatment of repetitive ventricular tachycardia." | 7.67 | [Comparative study on the efficacy of disopyramide and propafenone in the prevention of the recurrence of ventricular tachycardia]. ( Bomba, E; Bracchetti, D; Capucci, A; Lombardi, G; Naccarella, F; Palmieri, M, 1984) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 7.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "The efficacy of intravenous cibenzoline (3 mg/kg), propafenone (4 mg/kg), and procainamide (20 mg/kg) against inducible sustained and nonsustained ventricular tachycardias (VT) was evaluated in 12 conscious dogs with chronic isolated right ventricular (RV) infarction." | 7.67 | The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide. ( Ino, T; Karagueuzian, HS; Mandel, WJ; Meesmann, M; Ohta, M; Peter, T; Sugi, K, 1986) |
| "During treatment with the class Ic antiarrhythmic agent propafenone, the drug appeared to cause malignant ventricular tachyarrhythmias in five patients." | 7.67 | Malignant ventricular tachyarrhythmias in association with propafenone treatment. ( Bilgin, Y; Buss, J; Neuss, H; Schlepper, M, 1985) |
| "Propafenone (P), a class IC antiarrhythmic drug, was tested intravenously and orally in the curative and preventive treatment of sustained (VTS) and non-sustained (VTNS) ventricular tachycardia." | 7.67 | [Treatment of ventricular tachycardia with propafenone. Parallel study of ventricular provocation tests]. ( Balleh, H; Cosnay, P; Faućhier, JP; Huguet, R; Moquet, B; Rouesnel, P; Van Viet, H, 1987) |
| "Thirty children aged from 3 months to 20 years were treated with propafenone 250 to 650 mg/m2 divided into 2 to 4 daily doses, for a mean period of 14 months (range: 4 days to 5 years); 8 had chronic atrial tachycardia, 9 had junctional arrhythmia and 13 had ventricular arrhythmia." | 7.67 | [Anti-arrhythmia efficacy of propafenone in children. Apropos of 30 cases]. ( Batisse, A; Coumel, P; Do Ngoc, D; Fidelle, J; Loth, P; Lucet, V; Sidi, D; Villain, E; Vrancea, F, 1987) |
| "The electrophysiological effects of lidocaine (L) and propafenone (P) in chronic myocardial infarction in relation to tissue drug concentrations (TDC) are unknown." | 7.67 | Epicardial, endocardial and transmural mapping in assessing electrophysiological effects of 14-C lidocaine and 14-C propafenone on activation times in experimental chronic myocardial infarction. Correlations with myocardial drugs concentrations. ( Agarwal, JB; Bracchetti, D; Helfant, RH; Naccarella, FF; Weintraub, WS, 1984) |
| "Electrophysiologic and hemodynamic studies were performed before and after intravenous infusion of a new antiarrhythmic agent, propafenone, in 28 patients with recurrent ventricular tachycardia." | 7.67 | Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. ( DiCarlo, L; Morady, F; Scheinman, MM; Schwartz, AB; Shapiro, W; Shen, EN; Sung, RJ, 1984) |
| "We describe a case of acute myocardial infarction complicated by atrial and ventricular arrhythmias in which it was possible to verify the effectiveness of lidocaine, mexiletine and propafenone." | 7.67 | Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report. ( Aguglia, F; De Marzio, P; Gnecchi, M, 1985) |
| "The electrophysiologic effects and response to programmed ventricular stimulation of intravenous propafenone, an experimental antiarrhythmic agent, were studied in a group of 14 patients with both clinical and induced sustained ventricular tachycardia." | 7.67 | Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation. ( Buxton, AE; Cassidy, DM; Doherty, JU; Josephson, ME; Kienzle, MG; Marchlinski, FE; Waxman, HL, 1984) |
| "Lidocaine is most widely used for suppression of recurrent ventricular tachyarrhythmias by IV application." | 7.66 | [Therapy of ventricular tachyarrhythmias refractory to lidocaine with propafenone (author's transl)]. ( Glogar, D; Laimer, H; Zilcher, H, 1981) |
| "Previous bradyarrhythmias or sick sinus syndrome (SSS), and concomitant use of antiarrhythmic drugs were exclusion criteria." | 6.68 | Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? ( Alfieri, G; Barone, P; Bernasconi, G; Bonini, W; Botto, GL; Broffoni, T; Ferrari, G; Lombardi, R; Molteni, S, 1996) |
| "Propafenone was useful for management of atrial fibrillation after cardiac surgery both for control of rapid ventricular response and for conversion to sinus rhythm." | 6.66 | Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. ( Connolly, SJ; Davis, C; Hoffert, DL; Mulji, AS; Shragge, BW, 1987) |
| "Propafenone also showed a lower incidence of side effects." | 6.66 | Comparison of propafenone and disopyramide for treatment of chronic ventricular arrhythmias: placebo-controlled, double-blind, randomized crossover study. ( Ambrosioni, E; Bertaccini, P; Bracchetti, D; Cantelli, I; Naccarella, F; Palmieri, M, 1985) |
| "Propafenone was given to 60 children (mean age 4." | 5.29 | The use of propafenone in the treatment of tachyarrhythmias in children. ( Figini, A; Mauri, L; Vignati, G, 1993) |
| "Propafenone therapy was discontinued in each case." | 5.27 | Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone. ( Garan, H; McGovern, B; Ruskin, JN; Stavens, CS, 1985) |
| "Propafenone was less effective (mean effect 3." | 5.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| "Propafenone is an effective drug for the management of ventricular tachyarrhythmias, and may be used in patients with impaired left ventricular function." | 5.27 | Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. ( Abate, D; Allen, BJ; Brodsky, MA; Henry, WL, 1985) |
| "We studied the efficacy of propafenone in preventing atrial tachyarrhythmias after cardiac surgery, and the possible relationships between CYP2D6 polymorphism and the efficacy, pharmacokinetics, and tolerability of propafenone." | 5.13 | Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial. ( Bail, D; Böhm, JO; Delabar, U; Drescher, S; Eichelbaum, M; Engel, C; Fux, R; Gleiter, CH; Hellberg, KD; Hofmann, U; Igel, S; Jägle, C; Kivistö, KT; Marx, C; Meisner, C; Mörike, K; Rein, JG; Schaeffeler, E; Schwab, M; Wagner, F; Ziemer, G, 2008) |
| "The combination of propafenone and mexiletine is effective in suppressing the induction of ventricular tachycardia in some patients refractory to procainamide and propafenone alone." | 5.07 | Propafenone-mexiletine combination for the treatment of sustained ventricular tachycardia. ( Boone, J; Kerr, CR; Murdock, CJ; Yeung-Lai-Wah, JA, 1992) |
| " Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained." | 5.06 | Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. ( Campa, MA; Dubuc, M; Kus, T; Lambert, C; Rosengarten, M; Shenasa, M, 1989) |
| "The efficacy of propafenone in preventing induction of ventricular tachycardia was evaluated in 25 consecutive patients (mean age 62 +/- 8 years) with remote myocardial infarction who underwent programmed electrical stimulation for ventricular arrhythmia using up to three extra-stimuli after basic drive at the right ventricular apex." | 5.06 | Efficacy of propafenone in preventing ventricular tachycardia: inverse correlation with rate-related prolongation of conduction time. ( Dubuc, M; Kus, T; Lambert, C; Shenasa, M, 1990) |
| "Sixteen patients with ventricular tachycardia (VT) or nonfatal cardiac arrest were treated with propafenone (P), 900 mg/day." | 5.05 | Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. ( Connolly, SJ; Echt, DS; Kates, RE; Lebsack, CS; Mason, JW; Winkle, RA, 1983) |
| "The effects of the antiarrhythmic agent propafenone were evaluated in 25 patients with recurrent symptomatic ventricular tachycardia." | 5.05 | Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia. ( Browne, KF; Chilson, DA; Heger, JJ; Prystowsky, EN; Zipes, DP, 1985) |
| "The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD)." | 4.31 | Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. ( Alexander, ME; Bezzerides, VJ; DeWitt, ES; Dionne, A; Eberly, LM; Mah, DY; O'Leary, ET; Przybylski, R; Triedman, JK; Walsh, EP, 2023) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 3.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "We present two cases of proarrhythmia after propafenone treatment." | 3.74 | [Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter]. ( Jastrzebski, M, 2008) |
| "Amiodarone, a class III antiarrhythmic drug, is one of the most effective drugs used in the treatment of ventricular and paroxysmal supraventricular tachyarrhythmia." | 3.74 | Acute pancreatitis and amiodarone: a case report. ( Chen, CY; Chen, YY; Leung, KK, 2007) |
| "The effects of procainamide and propafenone on the composition of the excitable gap (EG) were studied in a canine model of atrial flutter (AFI) around the tricuspid valve." | 3.69 | Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. ( Derakhchan, K; Kus, T; Lambert, C; Pagé, P, 1994) |
| "A marked increase of chronic atrial pacing threshold resulting in loss of atrial capture, induced by propafenone, is reported in a patient with bradycardia-tachycardia syndrome." | 3.68 | Propafenone induced acute variation of chronic atrial pacing threshold: a case report. ( Boccadamo, R; Montefoschi, N, 1990) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 3.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "To clarify the risk-benefit ratio involved in association of antiarrhythmic drugs, a combined therapy of amiodarone and propafenone was tested by means of continuous electrocardiographic monitoring, analysis of levels of the drug in the plasma and programmed electrical stimulation in a selected group of 10 patients who had left ventricular dysfunction and spontaneous relapses of sustained ventricular tachycardia despite treatment with amiodarone." | 3.68 | The use of associated propafenone in patients with amiodarone-resistant ventricular tachycardia. ( Camerini, F; Chersevani, D; Dreas, L; Humar, F; Maras, P; Morgera, T, 1991) |
| "To determine the electrophysiological properties of oral propafenone, 50 patients (39 male and 11 female, aged 31 to 80 years) with sustained ventricular tachycardia or ventricular fibrillation underwent serial electrophysiological drug testing, using propafenone (750 to 900 mg daily) as the anti-arrhythmic regimen of first choice." | 3.68 | Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation. ( Frohner, K; Hief, C; Podczeck, A; Steinbach, KK; Stix, G, 1991) |
| "105 sequential patients with ventricular arrhythmias in a basal ECG-H recording, that were evaluated within 1 year with a new recording on amiodarone or propafenone, without major clinical events or therapeutic changes between the two recordings." | 3.68 | [Amiodarone and propafenone: evaluation using serial Holter recordings in patients with ventricular arrhythmia]. ( Adragão, P; Bonhorst, D; Seabra-Gomes, R; Ventosa, A, 1990) |
| "Propafenone (P), a class IC antiarrhythmic drug, was tested intravenously and orally in the curative and preventive treatment of sustained (VTS) and non-sustained (VTNS) ventricular tachycardia." | 3.67 | [Treatment of ventricular tachycardia with propafenone. Parallel study of ventricular provocation tests]. ( Balleh, H; Cosnay, P; Faućhier, JP; Huguet, R; Moquet, B; Rouesnel, P; Van Viet, H, 1987) |
| "Propafenone, a new antiarrhythmic drug, was administered to 60 patients with a history of refractory ventricular tachyarrhythmias, including ventricular fibrillation in 16 and ventricular tachycardia (VT) in 44." | 3.67 | Propafenone: noninvasive evaluation of efficacy. ( Cytryn, R; Lown, B; Podrid, PJ, 1984) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 3.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "Twenty-six patients had ventricular tachycardia initiated at control electrophysiologic study and had a repeat study during oral propafenone therapy." | 3.67 | Antiarrhythmic and electrophysiologic effects of oral propafenone. ( Chilson, DA; Heger, JJ; Hubbard, J; Miles, WM; Prystowsky, EN; Zipes, DP, 1984) |
| "The efficacy of intravenous cibenzoline (3 mg/kg), propafenone (4 mg/kg), and procainamide (20 mg/kg) against inducible sustained and nonsustained ventricular tachycardias (VT) was evaluated in 12 conscious dogs with chronic isolated right ventricular (RV) infarction." | 3.67 | The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide. ( Ino, T; Karagueuzian, HS; Mandel, WJ; Meesmann, M; Ohta, M; Peter, T; Sugi, K, 1986) |
| "Propafenone was administered to 29 patients who had multiple episodes of recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) despite previous antiarrhythmic therapy." | 3.67 | Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy. ( Heger, JJ; Hubbard, J; Miles, WM; Prystowsky, EN; Zipes, DP, 1984) |
| "0 mg/kg body weight) and oral (300 to 375 mg/d) diprafenone was studied in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia." | 3.67 | Diprafenone for treatment of Wolff-Parkinson-White syndrome. ( Geiger, M; Kuck, KH; Kunze, KP; Schlüter, M, 1989) |
| "The electrophysiologic effects and response to programmed ventricular stimulation of intravenous propafenone, an experimental antiarrhythmic agent, were studied in a group of 14 patients with both clinical and induced sustained ventricular tachycardia." | 3.67 | Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation. ( Buxton, AE; Cassidy, DM; Doherty, JU; Josephson, ME; Kienzle, MG; Marchlinski, FE; Waxman, HL, 1984) |
| "We describe a case of acute myocardial infarction complicated by atrial and ventricular arrhythmias in which it was possible to verify the effectiveness of lidocaine, mexiletine and propafenone." | 3.67 | Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report. ( Aguglia, F; De Marzio, P; Gnecchi, M, 1985) |
| "Electrophysiologic and hemodynamic studies were performed before and after intravenous infusion of a new antiarrhythmic agent, propafenone, in 28 patients with recurrent ventricular tachycardia." | 3.67 | Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. ( DiCarlo, L; Morady, F; Scheinman, MM; Schwartz, AB; Shapiro, W; Shen, EN; Sung, RJ, 1984) |
| "Thirty-two men with chronic ventricular arrhythmias responded to propafenone, a new potent antiarrhythmic agent, in short-term trials with 85% or greater reduction of total ventricular premature complexes (VPCs) per hour, 95% or greater reduction of ventricular couplets (VCs) per hour, and 100% abolition of ventricular tachycardia (VT) beats per 24 hours." | 3.67 | Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience. ( Baker, BJ; de Soyza, N; Dinh, H; Murphy, ML, 1988) |
| "The electrophysiological effects of lidocaine (L) and propafenone (P) in chronic myocardial infarction in relation to tissue drug concentrations (TDC) are unknown." | 3.67 | Epicardial, endocardial and transmural mapping in assessing electrophysiological effects of 14-C lidocaine and 14-C propafenone on activation times in experimental chronic myocardial infarction. Correlations with myocardial drugs concentrations. ( Agarwal, JB; Bracchetti, D; Helfant, RH; Naccarella, FF; Weintraub, WS, 1984) |
| "Thirty children aged from 3 months to 20 years were treated with propafenone 250 to 650 mg/m2 divided into 2 to 4 daily doses, for a mean period of 14 months (range: 4 days to 5 years); 8 had chronic atrial tachycardia, 9 had junctional arrhythmia and 13 had ventricular arrhythmia." | 3.67 | [Anti-arrhythmia efficacy of propafenone in children. Apropos of 30 cases]. ( Batisse, A; Coumel, P; Do Ngoc, D; Fidelle, J; Loth, P; Lucet, V; Sidi, D; Villain, E; Vrancea, F, 1987) |
| "The purpose of our study was to assess the efficacy of Propafenon in comparison with Disopyramide in the long-term treatment of repetitive ventricular tachycardia." | 3.67 | [Comparative study on the efficacy of disopyramide and propafenone in the prevention of the recurrence of ventricular tachycardia]. ( Bomba, E; Bracchetti, D; Capucci, A; Lombardi, G; Naccarella, F; Palmieri, M, 1984) |
| "The effect of oral propafenone on prevention of pacing-induced ventricular tachycardia (VT) was studied in 11 patients." | 3.67 | [Treatment of recurrent ventricular tachycardias using oral propafenone]. ( Cointe, R; Gérard, R; Labrunie, P; Lévy, S; Metge, M; Valeix, B; Vrancea, F, 1985) |
| "The postulated beta adrenoceptor blocking properties of the new antiarrhythmic drug propafenone were studied by in vivo comparison against placebo and propranolol in the antagonism of both exercise- and isoproterenol-induced tachycardia and by in vitro radioligand binding studies of animal and human left ventricular muscle membrane preparations." | 3.67 | Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. ( McLeod, AA; Shand, DG; Stiles, GL, 1984) |
| "During treatment with the class Ic antiarrhythmic agent propafenone, the drug appeared to cause malignant ventricular tachyarrhythmias in five patients." | 3.67 | Malignant ventricular tachyarrhythmias in association with propafenone treatment. ( Bilgin, Y; Buss, J; Neuss, H; Schlepper, M, 1985) |
| "Lidocaine is most widely used for suppression of recurrent ventricular tachyarrhythmias by IV application." | 3.66 | [Therapy of ventricular tachyarrhythmias refractory to lidocaine with propafenone (author's transl)]. ( Glogar, D; Laimer, H; Zilcher, H, 1981) |
| "Previous bradyarrhythmias or sick sinus syndrome (SSS), and concomitant use of antiarrhythmic drugs were exclusion criteria." | 2.68 | Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? ( Alfieri, G; Barone, P; Bernasconi, G; Bonini, W; Botto, GL; Broffoni, T; Ferrari, G; Lombardi, R; Molteni, S, 1996) |
| "Propafenone was useful for management of atrial fibrillation after cardiac surgery both for control of rapid ventricular response and for conversion to sinus rhythm." | 2.66 | Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. ( Connolly, SJ; Davis, C; Hoffert, DL; Mulji, AS; Shragge, BW, 1987) |
| "Propafenone also showed a lower incidence of side effects." | 2.66 | Comparison of propafenone and disopyramide for treatment of chronic ventricular arrhythmias: placebo-controlled, double-blind, randomized crossover study. ( Ambrosioni, E; Bertaccini, P; Bracchetti, D; Cantelli, I; Naccarella, F; Palmieri, M, 1985) |
| " With the intravenous administration of the drug in a dosage of 1." | 2.65 | [Propafenon therapy of arrhythmias in infancy and childhood (author's transl)]. ( Eigster, G; Weber, H; Wesselhoeft, H, 1981) |
| "Both adenosine and carbachol were found to directly inhibit If in human atrial myocytes by shifting the activation curves to more negative potentials." | 1.30 | Modulation of the hyperpolarization-activated inward current (If) by antiarrhythmic agents in isolated human atrial myocytes. ( Beuckelmann, DJ; Hoppe, UC, 1998) |
| "Propafenone was given to 60 children (mean age 4." | 1.29 | The use of propafenone in the treatment of tachyarrhythmias in children. ( Figini, A; Mauri, L; Vignati, G, 1993) |
| "The tachycardia was refractory to chest tump and intravenous standard drugs (lidocaine and propafenone)." | 1.28 | [Termination of ventricular tachycardia by noninvasive methods]. ( Magnani, A; Occhetta, E; Perucca, A; Piccinino, C; Rognoni, G; Rossi, P, 1991) |
| "Chaotic atrial tachycardia (n = 3) and junctional ectopic tachycardia (n = 2) were controlled after successful intravenous therapy." | 1.28 | Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias. ( Kallfelz, HC; Paul, T; Reimer, A, 1991) |
| "Evaluation revealed mitral valve prolapse with minimal mitral regurgitation, and normal left ventricular size and function." | 1.28 | New onset ventricular tachycardia during pregnancy. ( Braverman, AC; Bromley, BS; Rutherford, JD, 1991) |
| "Thus propafenone can produce rate-dependent failure of ventricular capture which is associated with marked prolongation of refractoriness and QRS duration suggesting a marked use-dependent drug effect in selected patients." | 1.28 | Rate-dependent failure of ventricular capture in patients treated with oral propafenone. ( Almendral, J; Arenal, A; Delcan, JL; Josephson, ME; San Román, D; Soriano, J, 1992) |
| "Antiarrhythmic drugs may induce congestive heart failure in patients with malignant ventricular arrhythmias and depressed left ventricular (LV) function." | 1.28 | Changes in cardiac output determined by continuous-wave Doppler echocardiography during propafenone or mexiletine drug testing. ( Lampert, S; Lange, H; Lown, B; Sutton, MS, 1990) |
| "Two patients with recurrences of sustained VT in this group were later successfully treated with propafenone, 900 mg/day; overall, 8 of 9 patients with recurrences of sustained VT were successfully treated with 900 mg/day." | 1.27 | Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment. ( Ambrosioni, E; Bracchetti, D; Marchesini, B; Naccarella, F; Palmieri, M, 1984) |
| "In cases of non-immune hydrops fetalis caused by tachyarrhythmias, the transplacental passage of antiarrhythmic drugs may be hampered." | 1.27 | Direct intrauterine fetal treatment of fetal tachyarrhythmia with severe hydrops fetalis by antiarrhythmic drugs. ( Bald, R; Gembruch, U; Hansmann, M, 1988) |
| "Propafenone was less effective (mean effect 3." | 1.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| "Emergency treatment of cardiac arrhythmias was required in 41 newborn and infants aged two days to 9 months (mean 77 days) from July 1977 until September 1981." | 1.27 | [Emergency treatment of arrhythmias in neonates and infants]. ( Eigster, G; Weber, H; Wesselhoeft, H, 1983) |
| " If side effects intervene that may cause continued therapy to be intolerable, changing the antiarrhythmic agent, as opposed to decreasing the dosage to an ineffective range, may be appropriate." | 1.27 | New directions in antiarrhythmic drug therapy. ( Somberg, JC, 1984) |
| " The latter, however, was taking antiarrhythmic drugs at a dosage less than that proved to be effective during electropharmacological testing." | 1.27 | [Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation]. ( Delise, P; Di Pede, F; Piccolo, E; Raviele, A, 1984) |
| "Propafenone is an effective drug for the management of ventricular tachyarrhythmias, and may be used in patients with impaired left ventricular function." | 1.27 | Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. ( Abate, D; Allen, BJ; Brodsky, MA; Henry, WL, 1985) |
| "Propafenone therapy was discontinued in each case." | 1.27 | Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone. ( Garan, H; McGovern, B; Ruskin, JN; Stavens, CS, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 52 (54.74) | 18.7374 |
| 1990's | 35 (36.84) | 18.2507 |
| 2000's | 6 (6.32) | 29.6817 |
| 2010's | 1 (1.05) | 24.3611 |
| 2020's | 1 (1.05) | 2.80 |
| Authors | Studies |
|---|---|
| Przybylski, R | 1 |
| Eberly, LM | 1 |
| Alexander, ME | 1 |
| Bezzerides, VJ | 1 |
| DeWitt, ES | 1 |
| Dionne, A | 1 |
| Mah, DY | 1 |
| Triedman, JK | 1 |
| Walsh, EP | 1 |
| O'Leary, ET | 1 |
| Li, X | 1 |
| Zhang, Y | 2 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Ge, H | 1 |
| Jastrzebski, M | 1 |
| Biffi, A | 1 |
| Pelliccia, A | 1 |
| Verdile, L | 1 |
| Fernando, F | 1 |
| Spataro, A | 1 |
| Caselli, S | 1 |
| Santini, M | 1 |
| Maron, BJ | 1 |
| Büyükavci, M | 1 |
| Olgun, H | 1 |
| Kertmen, B | 1 |
| Tan, H | 1 |
| Ceviz, N | 1 |
| Haque, A | 1 |
| Kannankeril, PJ | 1 |
| Chen, YY | 1 |
| Chen, CY | 1 |
| Leung, KK | 1 |
| Mörike, K | 1 |
| Kivistö, KT | 1 |
| Schaeffeler, E | 1 |
| Jägle, C | 1 |
| Igel, S | 1 |
| Drescher, S | 1 |
| Fux, R | 1 |
| Marx, C | 1 |
| Hofmann, U | 1 |
| Engel, C | 1 |
| Wagner, F | 1 |
| Delabar, U | 1 |
| Meisner, C | 1 |
| Bail, D | 1 |
| Böhm, JO | 1 |
| Gleiter, CH | 1 |
| Ziemer, G | 1 |
| Rein, JG | 1 |
| Hellberg, KD | 1 |
| Eichelbaum, M | 1 |
| Schwab, M | 1 |
| Inama, G | 3 |
| Guareneiro, M | 1 |
| Disertori, M | 3 |
| Camin, G | 1 |
| Fiorentini, F | 1 |
| Nicasi, L | 1 |
| Furlanello, F | 5 |
| McLeod, AA | 1 |
| Stiles, GL | 1 |
| Shand, DG | 1 |
| Somberg, JC | 1 |
| Gmeiner, R | 1 |
| Sterz, H | 1 |
| Weber, H | 2 |
| Eigster, G | 2 |
| Wesselhoeft, H | 2 |
| Lüderitz, B | 2 |
| Coumel, P | 3 |
| Leclercq, JF | 1 |
| Assayag, P | 1 |
| Connolly, SJ | 2 |
| Kates, RE | 1 |
| Lebsack, CS | 1 |
| Echt, DS | 1 |
| Mason, JW | 1 |
| Winkle, RA | 1 |
| Heger, JJ | 4 |
| Prystowsky, EN | 4 |
| Zipes, DP | 4 |
| Palmieri, M | 3 |
| Capucci, A | 1 |
| Lombardi, G | 1 |
| Naccarella, F | 3 |
| Bomba, E | 1 |
| Bracchetti, D | 4 |
| Marchesini, B | 1 |
| Ambrosioni, E | 2 |
| Chilson, DA | 2 |
| Miles, WM | 2 |
| Hubbard, J | 2 |
| Podrid, PJ | 1 |
| Cytryn, R | 1 |
| Lown, B | 2 |
| Raviele, A | 1 |
| Di Pede, F | 1 |
| Delise, P | 1 |
| Piccolo, E | 1 |
| Naccarella, FF | 1 |
| Agarwal, JB | 1 |
| Weintraub, WS | 1 |
| Helfant, RH | 1 |
| Vergara, G | 2 |
| Guarnerio, M | 2 |
| Bettini, R | 2 |
| Durante, G | 1 |
| Stirpe, E | 1 |
| von Philipsborn, G | 1 |
| Gries, J | 1 |
| Hofmann, HP | 1 |
| Kreiskott, H | 1 |
| Kretzschmar, R | 1 |
| Müller, CD | 1 |
| Raschack, M | 1 |
| Teschendorf, HJ | 1 |
| Fidelle, J | 2 |
| Shen, EN | 1 |
| Sung, RJ | 1 |
| Morady, F | 1 |
| Schwartz, AB | 1 |
| Scheinman, MM | 1 |
| DiCarlo, L | 1 |
| Shapiro, W | 1 |
| Nathan, AW | 1 |
| Bexton, RS | 1 |
| Hellestrand, KJ | 1 |
| Camm, AJ | 1 |
| Kulbertus, H | 1 |
| Doherty, JU | 1 |
| Waxman, HL | 1 |
| Kienzle, MG | 1 |
| Cassidy, DM | 1 |
| Marchlinski, FE | 2 |
| Buxton, AE | 1 |
| Josephson, ME | 3 |
| Marino, RL | 1 |
| Serufo, JC | 1 |
| de Souza, LS | 1 |
| Marino, MA | 1 |
| Borges, MZ | 1 |
| Rabelo, RC | 1 |
| Bernardes, Rde C | 1 |
| de Almeida, RC | 1 |
| Rabelo, W | 1 |
| Neumann, G | 1 |
| Grube, E | 1 |
| Funke, H | 1 |
| Botti, G | 1 |
| Bonatti, V | 1 |
| Rolli, A | 1 |
| Karagueuzian, HS | 2 |
| Fujimoto, T | 1 |
| Katoh, T | 1 |
| Peter, T | 2 |
| McCullen, A | 1 |
| Mandel, WJ | 2 |
| Laimer, H | 1 |
| Glogar, D | 1 |
| Zilcher, H | 1 |
| Derakhchan, K | 1 |
| Pagé, P | 1 |
| Lambert, C | 3 |
| Kus, T | 3 |
| Bertoldi, A | 1 |
| Vignati, G | 1 |
| Mauri, L | 1 |
| Figini, A | 1 |
| Botto, GL | 1 |
| Bonini, W | 1 |
| Broffoni, T | 1 |
| Molteni, S | 1 |
| Lombardi, R | 1 |
| Alfieri, G | 1 |
| Barone, P | 1 |
| Bernasconi, G | 1 |
| Ferrari, G | 1 |
| Ito, S | 1 |
| Gow, R | 1 |
| Verjee, Z | 1 |
| Giesbrecht, E | 1 |
| Dodo, H | 1 |
| Freedom, R | 1 |
| Tonn, GR | 1 |
| Axelson, JE | 1 |
| Zalzstein, E | 1 |
| Rosenberg, HC | 1 |
| Koren, G | 1 |
| Hoppe, UC | 1 |
| Beuckelmann, DJ | 1 |
| Todt, H | 1 |
| Krumpl, G | 1 |
| Krejcy, K | 1 |
| Raberger, G | 1 |
| Hill, BC | 1 |
| Summers, RA | 1 |
| Courtney, KR | 1 |
| Yeung-Lai-Wah, JA | 1 |
| Murdock, CJ | 1 |
| Boone, J | 1 |
| Kerr, CR | 1 |
| Soriano, J | 1 |
| Almendral, J | 1 |
| Arenal, A | 1 |
| San Román, D | 1 |
| Delcan, JL | 1 |
| Lombardi, F | 1 |
| Finocchiaro, ML | 1 |
| Dalla Vecchia, L | 1 |
| Rech, R | 1 |
| Castelli, A | 1 |
| Pastine, J | 1 |
| Cappiello, E | 1 |
| Ventosa, A | 1 |
| Adragão, P | 1 |
| Bonhorst, D | 1 |
| Seabra-Gomes, R | 1 |
| Montefoschi, N | 1 |
| Boccadamo, R | 1 |
| Nielsen, H | 1 |
| Sørum, C | 1 |
| Rasmussen, V | 1 |
| Madsen, JK | 1 |
| Hansen, JF | 1 |
| Scanu, P | 1 |
| Grollier, G | 1 |
| Guilleman, D | 1 |
| Iselin, M | 1 |
| Bustany, P | 1 |
| Hurpe, JM | 1 |
| Potier, JC | 1 |
| Budde, T | 1 |
| Borggrefe, M | 1 |
| Podczeck, A | 2 |
| Martinez-Rubio, A | 1 |
| Breithardt, G | 1 |
| Callans, DJ | 1 |
| Hook, BG | 1 |
| Braverman, AC | 1 |
| Bromley, BS | 1 |
| Rutherford, JD | 1 |
| Winslow, E | 1 |
| Campbell, JK | 1 |
| Barron, E | 1 |
| Marshall, RJ | 1 |
| Muir, AW | 1 |
| Morgera, T | 1 |
| Dreas, L | 1 |
| Humar, F | 1 |
| Maras, P | 1 |
| Chersevani, D | 1 |
| Camerini, F | 1 |
| Goy, JJ | 1 |
| Fromer, M | 1 |
| Schlaepfer, J | 1 |
| Kappenberger, L | 1 |
| Frohner, K | 1 |
| Hief, C | 1 |
| Stix, G | 1 |
| Steinbach, KK | 1 |
| Reimer, A | 1 |
| Paul, T | 1 |
| Kallfelz, HC | 1 |
| Guccione, P | 1 |
| Drago, F | 1 |
| Di Donato, RM | 1 |
| Cicini, MP | 1 |
| Pasquini, L | 1 |
| Marino, B | 1 |
| Marcelletti, C | 1 |
| Ragonese, P | 1 |
| Occhetta, E | 1 |
| Piccinino, C | 1 |
| Perucca, A | 1 |
| Magnani, A | 1 |
| Rognoni, G | 1 |
| Rossi, P | 1 |
| Lecky, BR | 1 |
| Weir, D | 1 |
| Chong, E | 1 |
| Kowey, PR | 1 |
| Stohler, JL | 1 |
| Friehling, TD | 1 |
| Marinchak, RA | 1 |
| Villain, E | 2 |
| Bonnet, D | 1 |
| Kachaner, J | 1 |
| Le Bidois, J | 1 |
| Cohen, L | 1 |
| Piéchaud, JF | 1 |
| Sidi, D | 2 |
| Campbell, RW | 1 |
| Dal Forno, P | 1 |
| Cozzi, F | 1 |
| Köppel, C | 1 |
| Oberdisse, U | 1 |
| Heinemeyer, G | 1 |
| Dubuc, M | 2 |
| Shenasa, M | 2 |
| Lange, H | 1 |
| Lampert, S | 1 |
| Sutton, MS | 1 |
| Korsukewitz, J | 1 |
| Wegscheider, K | 1 |
| Schmutzler, H | 1 |
| Menozzi, C | 1 |
| Brignole, M | 1 |
| Monducci, I | 1 |
| Lolli, G | 1 |
| Kunze, KP | 1 |
| Schlüter, M | 1 |
| Geiger, M | 1 |
| Kuck, KH | 1 |
| Thormann, J | 1 |
| Kramer, W | 1 |
| Kremer, P | 1 |
| Schlepper, M | 2 |
| Petri, H | 1 |
| Kafka, W | 1 |
| Rudolph, W | 1 |
| Aguglia, F | 1 |
| Gnecchi, M | 1 |
| De Marzio, P | 1 |
| Campa, MA | 1 |
| Rosengarten, M | 1 |
| Lacroix, H | 1 |
| Frank, R | 1 |
| Tonet, JL | 1 |
| Fontaine, G | 1 |
| Wajman, A | 1 |
| Squeir, S | 1 |
| Grosgogeat, Y | 1 |
| Lucet, V | 1 |
| Do Ngoc, D | 1 |
| Batisse, A | 1 |
| Loth, P | 1 |
| Vrancea, F | 2 |
| Faućhier, JP | 1 |
| Rouesnel, P | 1 |
| Cosnay, P | 1 |
| Moquet, B | 1 |
| Huguet, R | 1 |
| Van Viet, H | 1 |
| Balleh, H | 1 |
| Gembruch, U | 1 |
| Hansmann, M | 1 |
| Bald, R | 1 |
| Dinh, H | 1 |
| Baker, BJ | 1 |
| de Soyza, N | 1 |
| Murphy, ML | 1 |
| Malfatto, G | 1 |
| Zaza, A | 1 |
| Forster, M | 1 |
| Sodowick, B | 1 |
| Danilo, P | 1 |
| Rosen, MR | 1 |
| Mulji, AS | 1 |
| Hoffert, DL | 1 |
| Davis, C | 1 |
| Shragge, BW | 1 |
| De Jaegere, P | 1 |
| Huyghens, L | 1 |
| Dewilde, P | 1 |
| Sugi, K | 1 |
| Ohta, M | 1 |
| Meesmann, M | 1 |
| Ino, T | 1 |
| Manz, M | 1 |
| Beermann, J | 1 |
| Gerckens, U | 1 |
| Cantelli, I | 1 |
| Bertaccini, P | 1 |
| Browne, KF | 1 |
| Cointe, R | 1 |
| Lévy, S | 1 |
| Metge, M | 1 |
| Labrunie, P | 1 |
| Valeix, B | 1 |
| Gérard, R | 1 |
| Stavens, CS | 1 |
| McGovern, B | 1 |
| Garan, H | 1 |
| Ruskin, JN | 1 |
| Buss, J | 1 |
| Neuss, H | 1 |
| Bilgin, Y | 1 |
| Brodsky, MA | 1 |
| Allen, BJ | 1 |
| Abate, D | 1 |
| Henry, WL | 1 |
4 reviews available for propafenone and Tachycardia
| Article | Year |
|---|---|
[Long-term drug therapy of reciprocating supraventricular tachycardia: re-examination of a selected series of cases, using computerized programs].
Topics: Acebutolol; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents | 1980 |
[Role of propafenone in anti-arrhythmia treatment].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Drug Interactions; Electrophysiology; Humans; Propafenone | 1993 |
[Incessant idiopathic ventricular tachycardia in infants].
Topics: Amiodarone; Cardiomyopathies; Child, Preschool; Electrocardiography; Female; Flecainide; Follow-Up S | 1990 |
Is drug treatment of tachyarrhythmias a science or a lottery?
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Flecainide; Humans; Propafenone; Tachycardia | 1990 |
16 trials available for propafenone and Tachycardia
| Article | Year |
|---|---|
Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytochrome P-450 CYP2D6; Double-Blind Method; Fem | 2008 |
[Propafenon therapy of arrhythmias in infancy and childhood (author's transl)].
Topics: Adolescent; Age Factors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Atrioventricu | 1981 |
Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Cardiac Catheterization; Cardiac Pacing, Artificial; C | 1983 |
[Ventricular tachycardia--Effects of propafenon by intravenous route. Comparative study with lidocaine].
Topics: Adult; Aged; Clinical Trials as Topic; Electrocardiography; Female; Humans; Injections, Intravenous; | 1981 |
Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary?
Topics: Administration, Oral; Age Factors; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Atr | 1996 |
Propafenone-mexiletine combination for the treatment of sustained ventricular tachycardia.
Topics: Adult; Aged; Drug Therapy, Combination; Electrocardiography; Female; Heart Ventricles; Humans; Male; | 1992 |
Propafenone versus quinidine slow-release for the treatment of chronic ventricular arrhythmias.
Topics: Adult; Aged; Cardiac Complexes, Premature; Chronic Disease; Delayed-Action Preparations; Double-Blin | 1990 |
Propafenone in the treatment of patients with malignant ventricular tachyarrhythmias.
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Propafenone; Tachycardia; Ventricular Fi | 1991 |
Propafenone for cardiac arrhythmias.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Heart Ventricles; Humans; Propafenone; Tachycardia | 1990 |
Efficacy of propafenone in preventing ventricular tachycardia: inverse correlation with rate-related prolongation of conduction time.
Topics: Cardiac Pacing, Artificial; Electrocardiography; Electrophysiology; Female; Heart Conduction System; | 1990 |
[Idiopathic ventricular tachyarrhythmia. Spontaneous variability and effect of various antiarrhythmic agents].
Topics: Adult; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Clinical Trials as Topic; Disopyramide; | 1985 |
[Therapy of ventricular arrhythmias with propafenone].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiac Pac | 1985 |
Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome.
Topics: Adult; Cardiac Pacing, Artificial; Clinical Trials as Topic; Double-Blind Method; Electrophysiology; | 1989 |
Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery.
Topics: Adult; Aged; Coronary Artery Bypass; Double-Blind Method; Heart Rate; Heart Ventricles; Humans; Male | 1987 |
Comparison of propafenone and disopyramide for treatment of chronic ventricular arrhythmias: placebo-controlled, double-blind, randomized crossover study.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; D | 1985 |
Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Clinical Tria | 1985 |
75 other studies available for propafenone and Tachycardia
| Article | Year |
|---|---|
Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2023 |
Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Dr | 2017 |
[Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bundle-Branch Blo | 2008 |
Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Cardiovascular Abnormalities | 2002 |
Ventricular tachycardia as a presenting symptom in a child with thrombotic thrombocytopenic purpura.
Topics: Adolescent; Anti-Arrhythmia Agents; Diagnosis, Differential; Electrocardiography; Female; Humans; Me | 2004 |
Respiratory distress in a young infant.
Topics: Acute Disease; Anti-Arrhythmia Agents; Bronchiolitis; Electrocardiography; Humans; Infant; Male; Pro | 2005 |
Acute pancreatitis and amiodarone: a case report.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Pancreatitis; Propafenone; | 2007 |
Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies.
Topics: Adenylyl Cyclases; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Double-Blind | 1984 |
New directions in antiarrhythmic drug therapy.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Benz | 1984 |
[Conservative therapy of supraventricular tachycardias].
Topics: Adrenergic beta-Antagonists; Ajmaline; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 1984 |
[Drug therapy of arrhythmia in coronary cardiopathy].
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneacetamides; Cardiac Comp | 1983 |
European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 1984 |
Drug therapy of cardiac arrhythmias.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Biological Availabili | 1983 |
[Comparative study on the efficacy of disopyramide and propafenone in the prevention of the recurrence of ventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Disopyramide; Drug Evaluation; Heart Ventricles; Humans; Propafenone; Propio | 1984 |
Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Chromatography, High Pressure Liquid; Dizziness; Female; Humans | 1984 |
Antiarrhythmic and electrophysiologic effects of oral propafenone.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Female; Heart Conduction System; Hu | 1984 |
Propafenone: noninvasive evaluation of efficacy.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Drug Evaluation; Electrocardiography; Exercise Test | 1984 |
Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Female; Humans | 1984 |
[Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation].
Topics: Adult; Aged; Amiodarone; Death, Sudden; Disopyramide; Drug Therapy, Combination; Electrocardiography | 1984 |
Epicardial, endocardial and transmural mapping in assessing electrophysiological effects of 14-C lidocaine and 14-C propafenone on activation times in experimental chronic myocardial infarction. Correlations with myocardial drugs concentrations.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carbon Radioisotopes; Coronary Circulation; D | 1984 |
[Sustained ventricular tachycardia: induced polymorphism. Clinical and electrophysiological aspects; therapeutic implications].
Topics: Adult; Aged; Ajmaline; Amiodarone; Electric Stimulation; Electrocardiography; Electrophysiology; Fem | 1984 |
Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.
Topics: Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Calcium Channel Blockers; Dogs | 1984 |
[Emergency treatment of arrhythmias in neonates and infants].
Topics: Arrhythmias, Cardiac; Bradycardia; Critical Care; Female; Heart Arrest; Heart Block; Heart Defects, | 1983 |
Problems of antiarrhythmic treatment in children.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Electrocardiography; Humans; Propaf | 1983 |
Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Electrophysiology; Female; Heart Conduction System; | 1984 |
Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent.
Topics: Anti-Arrhythmia Agents; Humans; Male; Middle Aged; Propafenone; Propiophenones; Tachycardia | 1984 |
[How and why treat supraventricular tachycardias].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Drug Evaluation; Humans; Pr | 1984 |
Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation.
Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart Conduction Sy | 1984 |
[The value of antitachycardia pacemaker therapy in patients with Wolff-Parkinson-White syndrome].
Topics: Anti-Arrhythmia Agents; Bundle of His; Digitalis Glycosides; Disopyramide; Electrocardiography; Huma | 1983 |
[Validity and limits of invasive pharmacological tests in the treatment of malignant ventricular hyperkinetic arrhythmias].
Topics: Adult; Aged; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Fe | 1983 |
Suppression of ventricular arrhythmias by propafenone, a new antiarrhythmic agent, during acute myocardial infarction in the conscious dog. A comparative study with lidocaine.
Topics: Animals; Arterial Occlusive Diseases; Coronary Disease; Depression, Chemical; Diastole; Dogs; Electr | 1982 |
[Therapy of ventricular tachyarrhythmias refractory to lidocaine with propafenone (author's transl)].
Topics: Administration, Oral; Adolescent; Adult; Aged; Drug Evaluation; Drug Resistance; Female; Heart Ventr | 1981 |
Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia.
Topics: Action Potentials; Anesthesia; Animals; Atrial Flutter; Atrial Function; Chloralose; Diastole; Disea | 1994 |
The use of propafenone in the treatment of tachyarrhythmias in children.
Topics: Administration, Oral; Child, Preschool; Electrocardiography; Female; Humans; Injections, Intravenous | 1993 |
Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Child; Child, Preschool; Female; Humans; Infant; Infan | 1998 |
Modulation of the hyperpolarization-activated inward current (If) by antiarrhythmic agents in isolated human atrial myocytes.
Topics: Adenosine; Anti-Arrhythmia Agents; Biological Clocks; Carbachol; Dose-Response Relationship, Drug; H | 1998 |
Mechanism of antiarrhythmic efficacy of propafenone as assessed by programmed electrical stimulation in conscious dogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Consciousness; Dogs; Electric Stimulation; El | 1992 |
d-Sotalol has opposite effects from encainide and propafenone on the proportion of episodes of ventricular tachycardia that are sustained in an experimental substrate for reentry.
Topics: Animals; Encainide; Heart Conduction System; Heart Rate; In Vitro Techniques; Male; Propafenone; Rab | 1992 |
Rate-dependent failure of ventricular capture in patients treated with oral propafenone.
Topics: Administration, Oral; Aged; Cardiac Pacing, Artificial; Electrocardiography; Heart Rate; Heart Ventr | 1992 |
Effects of mexiletine, propafenone and flecainide on signal-averaged electrocardiogram.
Topics: Adult; Aged; Aged, 80 and over; Electrocardiography, Ambulatory; Female; Flecainide; Heart Diseases; | 1992 |
[Amiodarone and propafenone: evaluation using serial Holter recordings in patients with ventricular arrhythmia].
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Electrocardiography, Am | 1990 |
Propafenone induced acute variation of chronic atrial pacing threshold: a case report.
Topics: Atrioventricular Node; Bradycardia; Cardiac Pacing, Artificial; Electrocardiography; Female; Humans; | 1990 |
Malignant ventricular tachycardia during propafenone treatment in a child with junctional automatic tachycardia: effectiveness of intravenous molar sodium lactate.
Topics: Atrioventricular Node; Bundle-Branch Block; Child, Preschool; Electrocardiography; Female; Humans; L | 1991 |
Acute and long-term efficacy of oral propafenone in patients with ventricular tachyarrhythmias.
Topics: Administration, Oral; Adult; Aged; Drug Evaluation; Electrophysiology; Female; Humans; Male; Middle | 1991 |
The mechanism of propafenone-induced slowing of ventricular tachycardia in man as defined by analysis of resetting response patterns.
Topics: Aged; Cardiac Pacing, Artificial; Electrocardiography; Heart Conduction System; Humans; Male; Middle | 1991 |
New onset ventricular tachycardia during pregnancy.
Topics: Adult; Electrocardiography; Electrophysiology; Female; Humans; Mitral Valve Insufficiency; Mitral Va | 1991 |
Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Estrenes; Female; | 1991 |
The use of associated propafenone in patients with amiodarone-resistant ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combinatio | 1991 |
Electrophysiologic effects of intravenous propafenone at rest, during isoproterenol infusion and during exercise in the Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Atrioventricular Node; Cardiac Catheterization; Electrocardiography; Electrophysi | 1991 |
Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Coronary Disease; Drug Evaluation; Electric St | 1991 |
Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Electrocardiography | 1991 |
Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Atrial Flutter; Chi-Square Distribution; Chi | 1991 |
[Termination of ventricular tachycardia by noninvasive methods].
Topics: Cardiac Pacing, Artificial; Heart Ventricles; Humans; Lidocaine; Male; Middle Aged; Propafenone; Tac | 1991 |
Exacerbation of myasthenia by propafenone.
Topics: Aged; Coronary Disease; Heart Ventricles; Humans; Male; Myasthenia Gravis; Neurologic Examination; P | 1991 |
Arrhythmogenic effects of antiarrhythmic drugs.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Middle Aged; Prop | 1990 |
Clinical course and outcome in class IC antiarrhythmic overdose.
Topics: Ajmaline; Anti-Arrhythmia Agents; Bicarbonates; Bradycardia; Drug Overdose; Flecainide; Hemoperfusio | 1990 |
Sorting out the mechanisms of antiarrhythmic drug action.
Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Electrophysiology; Heart Co | 1990 |
Changes in cardiac output determined by continuous-wave Doppler echocardiography during propafenone or mexiletine drug testing.
Topics: Cardiac Output; Depression, Chemical; Echocardiography, Doppler; Female; Heart Failure; Humans; Male | 1990 |
Noninvasive serial electrophysiological testing using an implanted pacemaker for management of recurrent ventricular tachycardia.
Topics: Aged; Amiodarone; Electrophysiology; Heart Ventricles; Humans; Male; Mexiletine; Pacemaker, Artifici | 1986 |
Diprafenone for treatment of Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrioventricular Node; Electric Stimulati | 1989 |
Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).
Topics: Anti-Arrhythmia Agents; Blood Pressure; Cardiac Catheterization; Catheterization; Female; Heart Cond | 1989 |
Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Dru | 1985 |
[Effect of oral propafenon on accessory pathways of atrioventricular conduction].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Electrocardiography; Female; Heart C | 1985 |
[Anti-arrhythmia efficacy of propafenone in children. Apropos of 30 cases].
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Female; Follow-Up Studies; Humans; | 1987 |
[Treatment of ventricular tachycardia with propafenone. Parallel study of ventricular provocation tests].
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Female; Heart Function Tests; Heart V | 1987 |
Direct intrauterine fetal treatment of fetal tachyarrhythmia with severe hydrops fetalis by antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetalis; Medigoxin; Preg | 1988 |
Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience.
Topics: Aged; Arrhythmias, Cardiac; Chronic Disease; Drug Administration Schedule; Electrocardiography; Huma | 1988 |
Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dogs; Electrophysiology; Guinea Pigs; Heart; In | 1988 |
Sustained ventricular tachycardia occurring during propafenone therapy.
Topics: Arrhythmias, Cardiac; Electrocardiography; Heart Ventricles; Humans; Male; Middle Aged; Propafenone; | 1987 |
The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Drug Eval | 1986 |
[Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle of His; Cardiomyopathy, Dilated; Coronary Diseas | 1986 |
[Treatment of recurrent ventricular tachycardias using oral propafenone].
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Electric Stimulation; Female; Heart Conduction S | 1985 |
Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone.
Topics: Aged; Anti-Arrhythmia Agents; Electric Stimulation; Electrophysiology; Female; Humans; Male; Middle | 1985 |
Malignant ventricular tachyarrhythmias in association with propafenone treatment.
Topics: Adult; Aged; Arrhythmias, Cardiac; Death, Sudden; Electrocardiography; Humans; Male; Middle Aged; Pr | 1985 |
Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Electrophysiology; E | 1985 |